[
  {
      "role": "user",
      "content":
      "Article: The genomic landscape of sensitivity to arsenic trioxide uncovered by genome-wide CRISPR-Cas9 screening.\nSample:\n\n|    | 0        | 1         | 2           | 3        | 4        | 5             | 6       |\n|---:|:---------|:----------|:------------|:---------|:---------|:--------------|:--------|\n|  0 | id       | pos|score | pos|p-value | pos|fdr  | pos|rank | pos|goodsgrna | pos|lfc |\n|  1 | KEAP1    | 2.87e-10  | 2.59e-07    | 0.002475 | 1        | 3             | 10.566  |\n|  2 | C19orf43 | 9.42e-07  | 2.85e-06    | 0.018152 | 2        | 3             | 8.7163  |\n|  3 | PIGA     | 2.12e-05  | 7.56e-05    | 0.294554 | 3        | 2             | 4.5552  |\n|  4 | BBC3     | 2.24e-05  | 8e-05       | 0.294554 | 4        | 4             | 7.5085  |\n|  5 | PRKCSH   | 2.64e-05  | 9.25e-05    | 0.294554 | 5        | 2             | 1.8063  |\n\nHint: this is what MAGeCK statistics look like. Generally in the form '[pos/neg]|[summary statistic]' e.g. pos|p-value, neg|goodsgrna,  pos|lfc, etc."
  },
  {
      "role": "assistant",
      "content":"\n{\n'dataset_filename': 'chenGenomicLandscapeSensitivity2023_37251921_Table_1_ATO_normalized-total.gene_summa_t1',\n'header_row': '0',\n'sgRNA_sequence': 'None',\n'gene_identifier': 'HGNC gene symbol',\n'dataset_type': 'Data',\n'statistic_aggregation': 'Per gene',\n'metrics': ['MAGeCK statistics (postive selection)'],\n'conditions': ['ATO'],\n'condition_variables': ['Drug']\n}"
  },
  {
      "role": "user",
      "content": "Article: Genome scale CRISPR Cas9a knockout screen reveals genes that control glioblastoma susceptibility to the alkylating agent temozolomide\nSample:\n\n|    | 0                         |    1 |\n|---:|:--------------------------|-----:|\n|  0 | A1BG_CATCTTCTTTCACCTGAACG |  677 |\n|  1 | A1BG_CTCCGGGGAGAACTCCGGCG | 1248 |\n|  2 | A1BG_TCTCCATGGTGCATCAGCAC |   88 |\n|  3 | A1BG_TGGAAGTCCACTCCACTCAG |  842 |\n|  4 | A1CF_ACAGGAAGAATTCAGTTATG |  972 |\n|  5 | A1CF_AGTTATGTTAGGTATACCCG |  749 |"
  },
  {
      "role": "assistant",
      "content": "\n{\n'dataset_filename': 'awahGenomeScaleCRISPR2022_35990011_5953_DMSO_Day14_R2_sheet_t1',\n'header_row': 'None',\n'sgRNA_sequence': 'Concatenated',\n'gene_identifier': 'HGNC gene symbol',\n'dataset_type': 'Data',\n'statistic_aggregation': 'Per sgRNA',\n'metrics': ['Raw count'],\n'conditions': ['DMSO'],\n'condition_variables': ['Drug']\n}"
  },
  {
      "role": "user",
      "content": "Article: Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection\nSample:\n\n|    | 0                    | 1                     | 2                 |\n|---:|:---------------------|:----------------------|:------------------|\n|  0 | Barcode Sequence     | Annotated Gene Symbol | Annotated Gene ID |\n|  1 | AAAAAAAATCCGGACAATGG | SLC25A24              | 29957             |\n|  2 | AAAAAAAGGATGGTGATCAA | FASTKD3               | 79072             |\n|  3 | AAAAAAATGACATTACTGCA | BCAS2                 | 10286             |\n|  4 | AAAAAAATGTCAGTCGAGTG | GPR18                 | 2841              |\n|  5 | AAAAAACACAAGCAAGACCG | ZNF470                | 388566            |"
  },
  {
      "role": "assistant",
      "content": "\n{\n'dataset_filename': 'caiCooperationATMFanconi2020_32075772_NIHMS1563617-supplement-2_CP0041_20170705_compat_chip_t1',\n'header_row': '0',\n'sgRNA_sequence': 'None',\n'gene_identifier': 'HGNC gene symbol',\n'dataset_type': 'Lookup/Reference/Metadata',\n'statistic_aggregation': 'NA',\n'metrics': ['NA'],\n'conditions': ['NA'],\n'condition_variables': ['NA']\n}"
  },
  {
      "role": "user",
      "content": "Article: A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer\nSample:\n\n|    | 0                                                                       | 1          | 2          | 3          | 4          | 5     | 6     | 7     | 8     |\n|---:|:------------------------------------------------------------------------|:-----------|:-----------|:-----------|:-----------|:------|:------|:------|:------|\n|  0 | Supplementary Table 5. Raw counts from the cisplatin resistance screen. | nan        | nan        | nan        | nan        | nan   | nan   | nan   | nan   |\n|  1 | sgRNA                                                                   | Cisplatin1 | Cisplatin2 | Cisplatin3 | Cisplatin4 | DMSO1 | DMSO2 | DMSO3 | DMSO4 |\n|  2 | EHMT1-HGLibA_14685                                                      | 123        | 228        | 147        | 16         | 224   | 234   | 208   | 89    |\n|  3 | RALGPS2-HGLibA_40172                                                    | 5          | 2          | 7          | 167        | 15    | 155   | 36    | 90    |\n|  4 | HIST2H2BE-HGLibA_21534                                                  | 9          | 492        | 1          | 49         | 28    | 0     | 72    | 91    |\n|  5 | SGCA-HGLibA_43795                                                       | 173        | 87         | 273        | 82         | 142   | 111   | 174   | 156   |"
  },
  {
      "role": "assistant",
      "content": "\n{\n'dataset_filename': 'goodspeedWholegenomeCRISPRScreen2019_30414698_NIHMS1510205-supplement-1_Supplementary Table 5_t1',\n'header_row': '1',\n'sgRNA_sequence': 'None',\n'gene_identifier': 'HGNC gene symbol [MOD]',\n'dataset_type': 'Data',\n'statistic_aggregation': 'Per sgRNA',\n'metrics': ['Raw count'],\n'conditions': ['Cisplatin', 'DMSO'],\n'condition_variables': ['Drug']\n}"
  },
  {
      "role": "user",
      "content": "Article: MND1 and PSMC3IP Control PARP Inhibitor Sensitivity in Mitotic Cells\nSample:\n\n|    | 0       | 1                                                 | 2                                         | 3                                         | 4                          | 5                                          | 6                                            | 7                             | 8                                       | 9                                         | 10                                        | 11                         | 12                                       | 13                                         | 14                                           | 15                            |\n|---:|:--------|:--------------------------------------------------|:------------------------------------------|:------------------------------------------|:---------------------------|:-------------------------------------------|:---------------------------------------------|:------------------------------|:----------------------------------------|:------------------------------------------|:------------------------------------------|:---------------------------|:-----------------------------------------|:-------------------------------------------|:---------------------------------------------|:------------------------------|\n|  0 | GeneID  | CRISPRn Viability Z score (olap and talaz screen) | CRISPRn Drug Effect Z score (olap screen) | CRISPRn Olaparib sgRNA Drug Effect Zcount | CRISPRn Olaparib Gene Rank | CRISPRn Drug Effect Z score (talaz screen) | CRISPRn Talazoparib sgRNA Drug Effect Zcount | CRISPRn Talazoparib Gene Rank | CRISPRi Viability Z score (olap screen) | CRISPRi Drug Effect Z score (olap screen) | CRISPRi Olaparib sgRNA Drug Effect Zcount | CRISPRi Olaparib Gene Rank | CRISPRi Viability Z score (talaz screen) | CRISPRi Drug Effect Z score (talaz screen) | CRISPRi Talazoparib sgRNA Drug Effect Zcount | CRISPRi Talazoparib Gene Rank |\n|  1 | EME1    | -1.1                                 | -5.7                         | 2                                         | 145.0             | -6.8                          | 4                                            | 92.1               | -1.0                       | -5.6                         | 4                                         | 69.2           | -1.5                        | -28.4                          | 0                                            | 1.2              |"
  },
  {
      "role": "assistant",
      "content": "\n{\n'dataset_filename': 'zelceskiMND1PSMC3IPControl2023_37163373_1-s2.0-S2211124723004953-mmc2_ST1A_t1',\n'header_row': '0',\n'sgRNA_sequence': 'None',\n'gene_identifier': 'HGNC gene symbol',\n'dataset_type': 'Data',\n'statistic_aggregation': 'Per gene',\n'metrics': ['Z-score'],\n'conditions': ['CRISPRi Talazoparib', 'CRISPRi Olaparib', 'CRISPRn Talazoparib', 'CRISPRn Olaparib', 'CRISPRn Olaparib + Talazoparib'],\n'condition_variables': ['CRISPR type', 'Drug']\n}"
  },
  {
    "role": "user",
    "content": "Article: MND1 and PSMC3IP Control PARP Inhibitor Sensitivity in Mitotic Cells\nSample:\n\n|    | 0       | 1                                       | 2                                   | 3                                       | 4                                   | 5                                      | 6                              | 7                               | 8                                 |\n|---:|:--------|:----------------------------------------|:------------------------------------|:----------------------------------------|:------------------------------------|:---------------------------------------|:-------------------------------|:--------------------------------|:----------------------------------|\n|  0 | GeneID  | LORD_MCF10ATP53/RB1mut_Olaparib_CRISPRn | LORD_MCF10ATP53mut_Olaparib_CRISPRn | LORD_MCF10A TP53mut_Talazoparib_CRISPRn | LORD_MCF10ATP53mut_Olaparib_CRISPRi | LORD_MCF10ATP53mut_Talazoparib_CRISPRi | Olivieri_RPE1_Olaparib_CRISRPn | Zimmerman_HELA_Olaparib_CRISPRn | DeWeirdt_A375_Talazoparib_CRISPRn |\n|  1 | A1BG    | 0.1                               | 0.3                           | 0.4                               | -0.5                          | 0.1                              | 1.2                      | -1.1                      | -0.5                        |\n|  2 | A1CF    | -2.7                              | -0.9                          | 2.0                               | 0.1                           | 0.6                              | -1.0                     | 0.6                       | -0.3                        |\n|  3 | A2M     | 0.1                               | 0.5                           | 0.1                               | -0.2                          | 1.3                              | -0.8                     | 0.8                       | 0.6                        |"
  },
  {
    "role": "assistant",
    "content": "\n{\n'dataset_filename': 'zelceskiMND1PSMC3IPControl2023_37163373_1-s2.0-S2211124723004953-mmc2_ST1I_t1',\n'header_row': '0',\n'sgRNA_sequence': 'None',\n'gene_identifier': 'HGNC gene symbol',\n'dataset_type': 'Data',\n'statistic_aggregation': 'Per gene',\n'metrics': ['Z-score'],\n'conditions': ['LORD MCF10A_TP53/RB1mut Olaparib CRISPRn', 'LORD MCF10A_TP53mut Olaparib CRISPRn', 'LORD MCF10A_TP53mut Talazoparib CRISPRn', 'LORD MCF10A_TP53mut Olaparib CRISPRi', 'LORD MCF10A_TP53mut Talazoparib CRISPRi', 'Olivieri RPE1 Olaparib CRISRPn', 'Zimmerman HELA Olaparib CRISPRn', 'DeWeirdt A375 Talazoparib CRISPRn'],\n'condition_variables': ['Study', 'Cell line', 'Drug', 'CRISPR type']\n}"
  }
]